Endocrine Society Shares ARPA-H Priorities

On August 3, Endocrine Society President Carol Wysham, MD, shared the Society’s recommendations and concerns about the proposal for a new federal agency, the Advanced Research Projects Agency for Health (ARPA-H) as part of a listening session with National Institutes of Health (NIH) Director Francis Collins.

Wysham highlighted diabetes as a prime example of a disease where treatment could be revolutionized through APRA-H-funded projects, and how ARPA-H could drive improvements in wearable devices for the measurement of a variety of parameters. She also encouraged the NIH and the White House Office on Science and Technology Policy (OSTP) leadership to ensure that equity is built into ARPA-H.

Endocrine Society President Carol Wysham, MD, (right) presents Endocrine Society comments on the development of ARPA-H at an NIH Listening Session attended by nearly 200 people as a sign language interpreter shares her message.

Collins appreciated our comments, in particular our remarks on the importance of health equity and shared some insight on how ARPA-H would select projects. Importantly, he noted that the project selection process is unlikely to involve external peer review, but instead would be guided by a series of questions describing the nature of the project and anticipated impact.

The Endocrine Society has been the only organization invited to present at more than one listening session, which reflects how endocrine science crosses multiple institutes at the NIH.

Previously, Endocrine Society President-Elect Ursula Kaiser, MD, presented our recommendations at a separate listening session focused on research related to the National Institute of Environmental Health Sciences (NIEHS). The Endocrine Society has been the only organization invited to present at more than one listening session, which reflects how endocrine science crosses multiple institutes at the NIH. It is unclear at this time how ARPA-H will advance, particularly because the federal appropriations process is at a standstill. We will continue to keep members apprised of new developments.

You may also like

  • Drug Pricing and Affordable Insulin Issues Take Precedence

    Action on drug pricing and access to affordable insulin has heated up in Congress as part of the consideration of a large budget reconciliation process. The Endocrine Society has been a leading advocate urging the Biden Administration and Congress to take action on drug pricing and has offered several policy recommendations, including allowing the government…

  • Endocrine Society Joins Rally for Medical Research Hill Day to Advocate for NIH Funding

    On September 23, the Endocrine Society will join a group of scientific societies, academic institutions, and other biomedical research advocates as part of the 9th Annual Rally for Medical Research. Rally participants will call on the Congress to make funding for the National Institutes of Health (NIH) a national priority and raise awareness about the…

Find more in